Skip to main content

Table 6 Repurposing agent trials between 2016 and 2020

From: Repurposed agents in the Alzheimer’s disease drug development pipeline

  2016 2017 2018 2019 2020
DMTs Symptomatic agents DMTs Symptomatic agents DMTs Symptomatic agents DMTs Symptomatic agents DMTs Symptomatic agents
Phase I 1 3 1 2 3 2 7 1 8 1
Phase II 10 7 11 9 15 10 19 7 28 4
Phase III 4 3 4 4 2 5 3 6 6 6
Total 15 13 16 15 20 17 29 14 42 11
  1. Abbreviations: DMT disease-modifying therapy